🔍
Conditional Tau Mouse Lines that Faithfully Recapitulate Alzheimer’s Disease-like Pathologies
Case ID:
C12997
Report of Invention:
4/8/2014
Web Published:
5/4/2017
Value Proposition:
Effective therapy for Alzheimer’s disease (AD), the most common form of dementia and a devastating illness for the elderly, remains a great unmet need. For translational research and preclinical drug development, animal models that faithfully mimic the cardinal pathological features of AD are critical. A major limitation of current mouse models is the lack of progressive AD-like neuropathology, especially the severe age-dependent neuronal loss in their brains. In an effort to produce an improved model of the disease, we generated and characterized new mouse models that conditionally express the four repeat domain of human tau with the ΔK280 mutation (Tau4R-ΔK280 mice). The Tau4R-ΔK280 mice not only develop AD-like tau pathologies, but also recapitulate the age-dependent neuronal loss seen in AD. Advantages include:
Transgenic mouse line conditionally expressing Tau4R-ΔK280 mimics salient features of AD
Suitable for cross-breeding with APP mice to recapitulate key pathological features of AD as well as tauopathy
Valuable tool for screening and discovery of novel AD therapeutics
Technical Details:
Johns Hopkins researchers have developed new lines of inducible Tau mice. The mice exhibit age- and dosage- dependent hyperphosphorylated tau aggregation with ensuing deposition of tau tangles, neuronal loss and forebrain atrophy. Importantly, deficits in working memory in these mouse models occur during the early stages of development of tauopathy. As observed in cases of AD, reactive astrogliosis is associated with severe neuronal loss in Tau4R-ΔK280 mice. Thus we have established a mouse model of tauopathy that mimic some salient features of AD. Crossbreeding of these mice with APP mice will create a mouse model showing tangles, plaques, neuronal loss and degeneration that will be useful for studying disease mechanisms and amenable for pre-clinical drug screening and validation of novel therapies for AD.
Publication(s)/Associated Cases:
Nat Commun. 2016 Jul 4;7:12082.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://jhu.technologypublisher.com/technology/25213
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum